MDL 74405

Drug Profile

MDL 74405

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Aventis
  • Class Anti-ischaemics; Benzopyrans; Heart failure therapies
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Myocardial ischaemia

Most Recent Events

  • 19 Jan 2017 Discontinued - Preclinical for Myocardial ischaemia in France
  • 01 Sep 1998 No-Development-Reported for Myocardial ischaemia in France (Unknown route)
  • 11 Dec 1995 An animal study has been added to the pharmacodynamics section for Ischaemic Heart Disease .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top